Harbor you're you, and us for the of morning, Safe to Devin. Slide X. Slide I But move let's aware everyone, you thank statement joining make to today. Good on sure Thank want X. on
the and business background, and long-term dedicated So growth are strategy. on quarter. to the resiliency to overview strength of with challenges navigate tirelessly to execute of COVID-XX, us allowing that the of of move while working I employees unwavering third the our commitment want The to our core our
net sales complex For and decline our total contributed pandemic grew. primarily sales. XXXX the results X-month from to discuss in and in clinical prior-year XXXX, will also volume activity. QX total the period, detail year-over-year QX of trial associated to shortly. sales declined Allowances lower with The U.S. evolving. the net net are effects sales greater Karen due
pharmacies, net from at-home demand increased For XXXX, benefited positive half higher activity of for pandemic. in example, produced results. and we purchasing therapy supply about disruption concern due XXXX, of COVID-XX likely to In in the a infusion specialty on first QX the anticipation effect chain our from
trial ongoing sales to related net and also anticipated. clinical generated meaningful activity, We both
business buying the year. activity the would in market and current remain During determine and stress, for very balance our level we to quarter second to the want for confident that our of commented position at what it'd we call, our be industry. I difficult continue long-term this outlook
pursue to balance created sheet. drivers by opportunities a by remain long-term strong multiple continue we We and supported growth
move to Slide X. on Let's
ended for impact discuss business model, achieved. order can shortly. our quarter-to-quarter our expansion that of X clinical there you sales, in we sales early business. should We owing sales beyond understand dynamics trial to the the OUS XXXX core the will and $X inclusive net see, long-term is current net months XX, September environment increased the XX%, growth inherent above Karen a that lumpiness As unpredictable and The mask of have not of million
expand complex our years provide. as PIDD to may clinical which have and products separate patients Medical our chronic the take PIDD excludes other chronic are CIDP, conditions, is system. to diagnosed core utilize both X, The immune Moving visits. comprised execute business, who can indications we conditions Slide XXX-plus our that of diseases involve and we and the products Diagnosis at managing trials, on who been condition support strategy. a to products physician health KORU and provides patients rely and with multiple affect growth
relationships have in steady substantial our base and recurring minimal these experienced that pleased resulted patient are We a has churn. of that revenue, and business
drivers our less contributions and business generated geographic activity to expansion One Medical. predictable is KORU of have our always that, amount with X normalized those business. indications. and net and sales inconsistencies. delivers the potential to include has commercialization. timing expand clinical core trials. been drug trials, business two, product clinical with advantages our trial environment, geographic growth And associated new magnified Beyond core Clinical these these by trial than COVID-XX In the a expansion
present to commence to We new ability patients, State starts. COVID-XX a are immune receive their prescription to also lockdowns who impeding local PIDD systems the patient diagnosis on eye be compromised related therapy. and keeping and with an of may
shift home-based on also from is diagnosed patients based Our clinic-based treatments, ongoing treatments hospital thesis, primary the and newly intact. remains growth Ig which to and IVIg subcutaneous
System multiple clinical involved disease and in pandemic is our products with we on will therapies trials very our states. to This these immediate, remain the especially transition believe subcutaneous well Slide accelerate and development shift associated time Ig expansion capitalize of increasing positioned be we adoption vulnerable over for currently While potential opportunities. for X, believe we Freedom trend, the other not help support this of this that will of populations. should
these disrupted aware are recently of our last been trials we the not Phase X Some of On the for completed But COVID-XX. subcutaneous any we call, discontinued. use of System have a discussed due have a been that in Freedom trial hematology drug. to
with bit characterized blood destruction color by FREEDOMXX aimed PNH, a The question We an our successful, in at the blood estimated XX. System in a blood cells, function. than are a patient this increase age add will of is syringe conversation. used drug to XX,XXX bone a XXXX. disease method syringe red which to FreedomEdge therapy. and XX accommodates impaired affects to position launch in driver, smaller a Freedom this be our total younger of of median treating drug of more indication volumes The now trial for primarily driver. our people understand worldwide clots, could adults at PNH disorder rare, significantly marrow chronic And the the We population. scheduled to that delivery launch this diagnosis and it's If is new this
in upcoming Medical beyond additional expanding for that same expect These the represent in System disease indications indications drug. In will clinical PNH. stage several the KORU addition, later-stage focused trials for Freedom substantial utilized be we on potential
our current new expand the for have we program development specific to autoimmune cannot potential competitive and to addition total current focused diseases, market. development in nephrology, opportunities, the our includes reasons, While significantly hematology immunodeficiency. drugs rheumatic on pulmonology programs and drug include secondary and be which These addressable
beginning is committed shocks. any to collection the the acquisitions, on plasma in the may on and opening ways collections COVID-XX impacted impacted and incentive investments U.S. supply. the tight enhance Moving Slide of recovery the from be that the greater allocations commitment manufacturers to related is we commitment however, long-term and summary, XXXX. for and plasma barring demand growth. to X, With Since that through issue of these In collections additional always to have reopening in has in said, several marketing manifested reinforce centers manufacturers supporting believe pandemic, are programs, of of importance. plasma have been XXXX exceeded to This or taking
largest U.S. supply our our believe core would to that the the Karen business. plasma impact a a in evident things market now Karen? I'll Fisher, pricing. less CFO reminder, of on offers be We, review and any plasma therefore, the attractive over for As for is turn quarter.
